Human-rat integrated microRNAs profiling identified a new neonatal cerebral hypoxic-ischemic pathway...

Area of Science:

• Neuroscience and Pharmacology
• Biochemistry and Molecular Biology

Background:

• Neonatal encephalopathy (NE) impacts neurodevelopment, with hypothermia as the sole treatment, necessitating pharmaceutical alternatives.
• Melatonin shows promise for hypoxic-ischemic (HI) brain injury, but human studies are limited by the unavailability of neonatal brain tissue.
• Understanding NE pathophysiology requires integrating data from animal models and human subjects.

Purpose of the Study:

• To investigate the therapeutic potential of melatonin in neonatal hypoxic-ischemic (HI) brain injury.
• To elucidate the common pathophysiological pathways in human NE and animal HI models.
• To validate a novel approach for studying NE pathophysiology using integrated animal and human data.

Main Methods:

• Comparative analysis of microRNA (miRNA) profiles from a human neonate with NE and HI rats treated with melatonin.
• Bioinformatic identification of common Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways between human and rat samples.
• Validation of identified pathways through investigation of key protein expression (PKCα, p-Akt, p-ERK) in rat brain cortexes.

Main Results:

• Upregulated miRNAs identified two common KEGG pathways: glioma and long-term potentiation, linked to HI brain injury and melatonin treatment.
• Melatonin treatment modulated protein expression in HI rats, with PKCα increasing and p-Akt/p-ERK returning to basal levels.
• Bioinformatics and protein expression analyses confirmed common pathways affected by HI brain injury and melatonin.

Conclusions:

• A unified neonatal cerebral melatonin-sensitive HI pathway was established through integrated analysis of human and animal data.
• This approach successfully bridged the gap in understanding NE pathophysiology by combining animal models with human subject data.
• The findings support melatonin as a potential therapeutic agent for neonatal encephalopathy and provide a validated methodology for future research.